Sign In
Buy CYTK
$80.01
+0.84 (+1.06%)
At Close: Jun 23, 2026
CYTK Posts a Wider-Than-Expected Q4 Loss, Advances Myqorzo Launch Plans
02:45pm, Wednesday, 25'th Feb 2026
CYTK reports a wider-than-expected Q4 loss as expenses rise, but Myqorzo wins FDA nod and global expansion advances, with $1.22B cash fueling 2026 catalysts.
Cytokinetics, Incorporated (CYTK) Q4 2025 Earnings Call Transcript
01:07am, Wednesday, 25'th Feb 2026
Cytokinetics, Incorporated (CYTK) Q4 2025 Earnings Call Transcript
Cytokinetics (CYTK) Reports Q4 Loss, Beats Revenue Estimates
08:31pm, Tuesday, 24'th Feb 2026
Cytokinetics (CYTK) came out with a quarterly loss of $1.5 per share versus the Zacks Consensus Estimate of a loss of $1.48. This compares to a loss of $1.26 per share a year ago.
Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update
04:00pm, Tuesday, 24'th Feb 2026
MYQORZO® Approved for Adults with Symptomatic Obstructive HCM in U.S., China and Europe; U.S. Launch Underway with First Prescriptions Dispensed within Days of Drug Availability Supplemental NDA fo
Cytokinetics Wins EU Approval for Cardiovascular Drug Myqorzo
10:35am, Wednesday, 18'th Feb 2026
CYTK secures EU approval for Myqorzo in symptomatic obstructive HCM, expanding its first commercial drug across major global markets.
Earnings Preview: Cytokinetics (CYTK) Q4 Earnings Expected to Decline
11:01am, Tuesday, 17'th Feb 2026
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
European Commission Approval Based on Results of SEQUOIA-HCM First European Launch Expected in Germany in Q2 2026 SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorpora
Cytokinetics to Announce Fourth Quarter Results on February 24, 2026
04:00pm, Thursday, 12'th Feb 2026
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 24, 2026 at 4
Cytokinetics Announces Recipients of Its Eighth Annual Communications Grant Program
07:30am, Monday, 09'th Feb 2026
Grants Awarded to Two Patient Advocacy Organizations to Support Communications and Community Outreach SOUTH SAN FRANCISCO, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasda
New York State Common Retirement Fund Has $2.63 Million Position in Cytokinetics, Incorporated $CYTK
04:16am, Sunday, 08'th Feb 2026
New York State Common Retirement Fund grew its stake in Cytokinetics, Incorporated (NASDAQ: CYTK) by 24.1% during the third quarter, according to the company in its most recent filing with the Securit
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Recommendation of “Moderate Buy” from Analysts
01:44am, Friday, 06'th Feb 2026
Shares of Cytokinetics, Incorporated (NASDAQ: CYTK - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the twenty-one research firms that are presently covering the company
MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Inc
The Law Offices of Frank R. Cruz Announces Investigation of Cytokinetics, Incorporated (CYTK) on Behalf of Investors
02:39pm, Thursday, 22'nd Jan 2026
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Cytokinetics, Incorporated (“Cytokinetics” or the “Company”)
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Tuesday, 20'th Jan 2026
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on January 15, 2026 it granted stock options to purchase an aggregate of 2
Cytokinetics, Incorporated (CYTK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
03:46pm, Monday, 12'th Jan 2026
Cytokinetics, Incorporated (CYTK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
